Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

TWEAK/TNFSF12 and LIGHT/TNFSF14 interactions in allergic esophagitis remodeling

Award Number: R01DK114457
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2018
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

TWEAK/TNFSF12 and LIGHT/TNFSF14 interactions in allergic esophagitis remodeling - ABSTRACT Eosinophilic Esophagitis (EoE) is an oral- and aero-antigen mediated allergic disease of increasing prevalence and incidence. EoE is characterized by esophageal fibrosis, rigidity, and smooth muscle hypertrophy, resulting in food impactions and strictures, vomiting, poor appetite, failure to thrive, and dysphagia. Chronic Th2-type inflammation of the esophagus in EoE can lead to fibrosis and other features of tissue remodeling that induce esophageal narrowing and associated food impactions and dysphagia. Current EoE treatments include antigen elimination diets and topical corticosteroids that can limit inflammation, but these measures may not control disease long term or reverse the course of esophageal remodeling and dysfunction. Our current lack of therapies that can halt or reverse EoE associated remodeling creates a pressing need for therapies since approximately 50% of patients have treatment resistant disease or inflammation that recurs despite ongoing therapy. In the first cycle of this grant, we demonstrated the presence of the TNF superfamily member, TNFSF14/LIGHT in all T cell subsets in the active EoE esophagus. Further, we demonstrated that esophagus fibroblasts were a major target of LIGHT, expressing both receptors (LTR and HVEM) for this cytokine. LIGHT induced differentiation of pathogenic and remodeling fibroblasts with increased pro-inflammatory gene transcription and the ability to interact with human eosinophils dependent on both its receptors. The role of LIGHT in EoE was also supported by studies in a robust murine EoE model where the absence of LIGHT protected from esophagus remodeling. New novel data from our labs suggests that the there is a complex and concerted action of several cytokines in the TNF superfamily in EoE that includes not only LIGHT but also TNFSF12/TWEAK. TWEAK and its receptor TNFRSF12A/Fn14 are induced in the active EoE esophagus. TWEAK and LIGHT induce both unique and overlapping inflammatory fibroblast transcriptional phenotypes with TWEAK having substantive effects on myofibroblasts. Based on our new data that LIGHT, TWEAK, IFN, and IL-13 are co-expressed in esophageal T cells, that LIGHT and TWEAK interact functionally with IFN and IL-13 to induce fibroblast inflammatory and remodeling gene expression, and that their receptors are expressed in esophageal tissue from EoE patients and co-expressed on esophageal fibroblasts, we propose to test the hypothesis that LIGHT, TWEAK, and their receptors orchestrate EoE remodeling by inducing pro- inflammatory and pro-remodeling fibroblasts. We utilize primary human esophageal cells, tissues, and biopsies, from normal and EoE patients, as well as murine models of allergic esophagitis with gene-deficient whole animal and fibroblast-specific Fn14 and LTR deficient mice. Pre-clinical therapeutic blocking strategies will inform the concerted action of TWEAK and LIGHT and their interactions with IL-13 and INF in EoE remodeling. These studies may lead to new and novel targets for therapeutic intervention in EoE.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	6	2/16/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $700,607 )
2025	2025	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	6	6/10/2025	NON-COMPETING CONTINUATION	$700,607
														Subtotal = $700,607

Issue Date FY: 2024 ( Subtotal = $745,047 )
2024	2024	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	5/22/2024	COMPETING CONTINUATION	$745,047
														Subtotal = $745,047

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	5/2/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $568,901 )
2021	2021	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	2/25/2021	NON-COMPETING CONTINUATION	$568,901
														Subtotal = $568,901

Issue Date FY: 2020 ( Subtotal = $574,928 )
2020	2020	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	2/27/2020	NON-COMPETING CONTINUATION	$574,928
														Subtotal = $574,928

Issue Date FY: 2019 ( Subtotal = $581,037 )
2019	2019	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	2/28/2019	NON-COMPETING CONTINUATION	$581,037
														Subtotal = $581,037

Issue Date FY: 2018 ( Subtotal = $626,140 )
2018	2018	LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	2/28/2018	NEW	$626,140
														Subtotal = $626,140

Grand Total All Awards = $3,796,660

Top

All Categories

About

Search

Reports

Data Submission

Award Information

TWEAK/TNFSF12 and LIGHT/TNFSF14 interactions in allergic esophagitis remodeling

Award Number: R01DK114457

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2018

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer